CTLA4 and neoplasm: Checkpoint inhibitors such as nivolumab or pembrolizumab (programmed cell death 1 or PD-1 inhibitors) and ipilimumab (a cytotoxic T-lymphocyte-associated protein 4 or CTLA-4 inhibitor) enhance the immune response to a tumor.